Market Overview

Impending Headwinds Blow Walgreens Rating Down To Equal-Weight

Impending Headwinds Blow Walgreens Rating Down To Equal-Weight
Related WBA
Vetr Recommends Walgreens As A Strong Buy
Wall Street's M&A Chatter From December 6: DaVita Medical Group, Cleantech-Brighten Holdings, Walgreens-GuoDa
Top 3 Picks In Consumer Defensive For 2018 (Seeking Alpha)

The bullish case for owning Walgreens Boots Alliance Inc (NASDAQ: WBA) has come to an end, says analysts at Morgan Stanley. The firm's Ricky Goldwasser downgrades Walgreens Boots' stock rating from Overweight to Equal-Weight with a price target lowered from $95 to $85.

Walgreens is expected to provide guidance on Oct. 25 and it will likely fall below consensus estimates, Goldwasser commented in her downgrade note (see Goldwasser's track record here). Specifically, the company could see an 11- to 14-cent headwind to its earnings per share after it was excluded from Silverscript, Envision and Aetna Medicare preferred networks. In fact, the exclusion could result in 4 to 5 million scripts shifting away from Walgreens' stores and into competitors.

PBM partnerships was once core to Walgreens' bullish thesis and succeeded in driving double-digit EPS growth throughout fiscal 2017, Goldwasser continued. But now rival CVS Health Corp (NYSE: CVS) is also offering its own preferred networks and will take over some market share within the preferred network space.

Accordingly, Walgreens' strength last year could reverse in fiscal 2018 and 2019, the analyst suggested. The company's operating income estimate for fiscal 2018 has now been lowered from $7.872 billion to $7.681 billion and 2019's estimates have also been revised from $8.388 billion to $7.991 billion.

Related Links:

Why Walgreens Is Important For E.L.F. Beauty Products

The Long Saga Of Walgreens-Rite Aid Finds Closure With Amended Deal
Image Credit: By Jazz Guy - Flickr: A great day in Manhattan, NYC., CC BY 2.0, via Wikimedia Commons

Latest Ratings for WBA

Dec 2017Deutsche BankInitiates Coverage OnHold
Nov 2017CitigroupMaintainsBuy
Nov 2017Leerink SwannDowngradesOutperformMarket Perform

View More Analyst Ratings for WBA
View the Latest Analyst Ratings

Posted-In: medicare Medicare Preferred NetworksAnalyst Color Downgrades Health Care Price Target Analyst Ratings General Best of Benzinga


Related Articles (CVS + WBA)

View Comments and Join the Discussion!

Partner Center